These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 19372173)

  • 1. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
    Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
    [No Abstract]   [Full Text] [Related]  

  • 3. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
    Pizzo PA
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy?
    Williams KJ
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i18-20. PubMed ID: 19372175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
    Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008.
    Bennett JE
    J Antimicrob Chemother; 2009 May; 63 Suppl 1(Suppl 1):i23-6. PubMed ID: 19372177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatment.
    Verweij PE; Maertens J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i31-5. PubMed ID: 19372180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Sugar AM
    Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial prophylaxis for infection in neutropenic patients.
    Bodey GP
    Curr Clin Top Infect Dis; 1988; 9():1-43. PubMed ID: 3077285
    [No Abstract]   [Full Text] [Related]  

  • 14. Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
    Aguilar-Guisado M; Espigado I; Cordero E; Noguer M; Parody R; Pachón J; Cisneros JM
    Bone Marrow Transplant; 2010 Jan; 45(1):159-64. PubMed ID: 19525983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
    Karthaus M; Hentrich M
    Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibiotics and antimycotics in oncology].
    Krcméry V
    Vnitr Lek; 1991; 37(7-8):695-702. PubMed ID: 1755212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
    Martino R; Viscoli C
    Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis.
    Blijlevens NM; Logan RM; Netea MG
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i36-40. PubMed ID: 19372181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis.
    Shenep JL
    NCI Monogr; 1990; (9):117-22. PubMed ID: 2342588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.